Inde - anglais - Central Drugs Standard Control Organization

macleods - iron (iii) hydroxide polymaltose complex eq.to elemental iron - inj - 20mg(ferric hydroxide with sucrose) - 5 ml

Inde - anglais - Central Drugs Standard Control Organization

g & g - iron (iii) hydroxide polymaltose complex eq.to elemental iron - inj - 20mg(ferric hydroxide with sucrose) - 2.5ml

Inde - anglais - Central Drugs Standard Control Organization

emcure - iron (iii) hydroxide polymaltose complex eq.to elemental iron - inj - 20mg(ferric hydroxide with sucrose) - 1

Irlande - anglais - HPRA (Health Products Regulatory Authority)

pharmacosmos a/s - iron (iii) hydroxide dextran complex - solution for injection/infusion - 50 milligram(s)/millilitre - iron, parenteral preparations

États-Unis - anglais - NLM (National Library of Medicine)

ropack inc. - ferric pyrophosphate citrate (unii: uby79oco9g) (ferric cation - unii:91o4lml611) - ferric cation 272 mg in 272 mg - triferic is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (hdd-ckd). triferic is not intended for use in patients receiving peritoneal dialysis. triferic has not been studied in patients receiving home hemodialysis. none risk summary there are no data with triferic use in pregnant women to inform a drug-associated risk. no teratogenicity was observed in animal reproduction studies with administration of ferric pyrophosphate citrate to pregnant rats and rabbits during organogenesis at doses 96 and 128 times, respectively, the maximum recommended human dose (mrhd) of 27.2 mg per dialysis [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. data animal data in a fertility and early embryonic development study in female rats, the maternally toxic ferric pyrophosphate citra

États-Unis - anglais - NLM (National Library of Medicine)

rockwell medical, inc - ferric pyrophosphate citrate (unii: uby79oco9g) (ferric cation - unii:91o4lml611) - ferric cation 5.44 mg in 1 ml - triferic is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (hdd-ckd). triferic is not intended for use in patients receiving peritoneal dialysis. triferic has not been studied in patients receiving home hemodialysis. none risk summary there are no data with triferic use in pregnant women to inform a drug-associated risk. no teratogenicity was observed in animal reproduction studies with administration of ferric pyrophosphate citrate to pregnant rats and rabbits during organogenesis at doses 96 and 128 times, respectively, the maximum recommended human dose (mrhd) of 27.2 mg per dialysis [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. data animal data in a fertility and early embryonic development study in female rats, the maternally toxic ferric py

États-Unis - anglais - NLM (National Library of Medicine)

american regent, inc. - ferric carboxymaltose (unii: 6897gxd6oe) (ferric cation - unii:91o4lml611) - ferric cation 50 mg in 1 ml - injectafer is indicated for the treatment of: •     iron deficiency anemia (ida) in: - adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. - adult patients who have non-dialysis dependent chronic kidney disease. adult patients who have non-dialysis dependent chronic kidney disease. •     iron deficiency in adult patients with heart failure and new york heart association class ii/iii to improve exercise capacity. injectafer is contraindicated in patients with a history of hypersensitivity to injectafer or any of its components [see warnings and precautions (5.1) ]. risk summary parenteral iron administration may be associated with hypersensitivity reactions [ see warnings and precautions (5.1)], which may have serious consequences, such as fetal bradycardia (see clinical considerations ). advise pregnant wome

États-Unis - anglais - NLM (National Library of Medicine)

nartex laboratorios homeopati cos, s.a. de c.v. - ferrosoferric phosphate (unii: 91gqh8i5f7) (ferrosoferric phosphate - unii:91gqh8i5f7), avena sativa pollen (unii: a7iky24tr7) (avena sativa pollen - unii:a7iky24tr7), cinchona officinalis whole (unii: 3sxm338giq) (cinchona officinalis whole - unii:3sxm338giq) - ferrosoferric phosphate 8 [hp_x] in 240 g - uses:  relieves symptoms such as: - fatigue - physical weakness - loss of strength as per homeopathic materia medica homeopathic medicine nartex labs revitalix alfalfa (medicago sativa l) cinchona (cinchona officinalis l) ferrosoferric phosphate mexican tradition net 8.12 fl oz (240 ml) relieves symptoms such as fatigue physical weakness and loss of strength

Australie - anglais - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - ferric derisomaltose, quantity: 4170 mg (equivalent: iron, qty mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - monofer is indicated for the treatment of iron deficiency in adults, under the following conditions:- when oral iron preparations are ineffective or cannot be used - where there is a clinical need to deliver iron rapidly the diagnosis must be based on laboratory tests.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - ferric derisomaltose, quantity: 2085 mg (equivalent: iron, qty mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - monofer is indicated for the treatment of iron deficiency in adults, under the following conditions:- when oral iron preparations are ineffective or cannot be used - where there is a clinical need to deliver iron rapidly the diagnosis must be based on laboratory tests.